Print

AVEG 005A/B

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) January 28, 1991
Env 2-3 Env gp130 B SF-2
Env 2-3 Protein
MTP-PE/MF59 Adjuvant Emulsion
USA 64
NCT00000972
http://clinicaltrials.gov/ct2/show/NCT00000972